Avexxin AS is a clinical stage pharmaceutical company focused on the development of small molecule therapies against chronic inflammatory diseases including psoriasis and chronic kidney disease. With numerous compounds in its preclinical pipeline, Avexxin’s R&D programs selectively target the intracellular enzyme Group IVa cPLA2a, a validated pro-inflammatory target (linked downstream to its effector NF-κB) in multiple disease indications. For further information, please visit: www.avexxin.com.